A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Trial Profile

A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ORION; ORION-1
  • Sponsors The Medicines Company
  • Most Recent Events

    • 07 May 2018 Results of effect of inclisiran on pre-specified secondary lipid and lipoprotein outcomes published in the Circulation.
    • 07 May 2018 Results presented in an the Medicines Company media release.
    • 07 May 2018 According to an the Medicines Company media release, results from this study is accepted for publication in Circulation, the Journal of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top